Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model

Cancer Gene Therapy

Volumn 20, Issue 10, 2013, Pages 544-551

  Huang, T T ^a   Hlavaty, J ^b   Ostertag, D ^a   Espinoza, F L ^a   Martin, B ^a   Petznek, H ^b   Rodriguez Aguirre, M ^a   Ibanez C E ^a   Kasahara, N ^c   Gunzburg, W ^b   Gruber, H E ^a   Pertschuk, D ^a   Jolly, D J ^a   Robbins, J M ^a  

^a Tocagen   (United States)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain cancer; Cytosine deaminase; Temodar; Toca 511

Indexed keywords

FLUCYTOSINE; TEMOZOLOMIDE; VOCIMAGENE AMIRETROREPVEC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CELL KILLING; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GENE TRANSFER; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; LONG TERM SURVIVAL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

MUS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CYTOSINE DEAMINASE; DACARBAZINE; DRUG SYNERGISM; FEMALE; FLUCYTOSINE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GLIOBLASTOMA; MICE; MICE, NUDE; RETROVIRIDAE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84886101402     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.51     Document Type: Article

References (35)

1. Perez OD, Logg CR, Hiraoka K, Diago O, Burnett R, Inagaki A et al. Design and selection of toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol Ther 2012; 20: 1689-1698.
2. Ostertag D, Amundson KK, Lopez Espinoza F, Martin B, Buckley T, Galvao da Silva AP et al. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro-Oncology 2012; 14: 145-159.
3. Trinh VA, Patel SP, Hwu WJ. The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf 2009; 8: 493-499.
4. Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res 2005; 11(Part 1): 6767-6771. (Pubitemid 41428729)
5. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004; 10: 1871-1874. (Pubitemid 38375541)
6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003. (Pubitemid 40349502)
7. Kokkinakis DM, Bocangel DB, Schold SC, Moschel RC, Pegg AE. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1- nitrosourea or temozolomide. Clin Cancer Res 2001; 7: 421-428. (Pubitemid 32183048)
8. Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol 2012; 107: 359-364.
9. Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ et al. Improved survival time trends for glioblastoma using the SEER 17 populationbased registries. J Neurooncol 2012; 107: 207-212.
10. Darefsky AS, King Jr JT, Dubrow R. Adult glioblastoma multiforme survival in the temozolomide era: a population-based analysis of Surveillance, Epidemiology, and End Results registries. Cancer 2012; 118: 2163-2172.
11. Yabroff KR, Harlan L, Zeruto C, Abrams J, Mann B. Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006. Neuro-Oncology 2012; 14: 351-359.
12. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996. (Pubitemid 40349501)
13. Chenoufi N, Raoul JL, Lescoat G, Brissot P, Bourguet P. In vitro demonstration of synergy between radionuclide and chemotherapy. J Nucl Med 1998; 39: 900-903. (Pubitemid 28216747)
14. Logg CR, Logg A, Tai CK, Cannon PM, Kasahara N. Genomic stability of murine leukemia viruses containing insertions at the Env-3′ untranslated region boundary. J Virol 2001; 75: 6989-6998. (Pubitemid 32641586)
15. Perzelova A, Macikova I, Mraz P, Bizik I, Steno J. Characterization of two new permanent glioma cell lines 8-MG-BA and 42-MG-BA. Neoplasma 1998; 45: 25-29. (Pubitemid 28157056)
16. Pohl U, Wick W, Weissenberger J, Steinbach JP, Dichgans J, Aguzzi A et al. Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor in GFAP-v-src-transgenic mice: comparison with established murine glioma cell lines. Int J Oncol 1999; 15: 829-834.
17. Tai CK, Wang WJ, Chen TC, Kasahara N. Single-shot multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol Ther 2005; 12: 842-851. (Pubitemid 41614479)
18. Hlavaty J, Jandl G, Liszt M, Petznek H, Konig-Schuster M, Sedlak J et al. Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma. J Neurooncol 2011; 102: 59-69.
19. Hill M, Norman A, Cunningham D, Findlay M, Nicolson V, Hill A et al. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 1995; 13: 1297-1302.
20. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology 2011; 13: 324-333.
21. Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004; 22: 610-616. (Pubitemid 41095063)
22. Smilowitz HM, Weissenberger J, Weis J, Brown JD, O'Neill RJ, Laissue JA. Orthotopic transplantation of v-src-expressing glioma cell lines into immunocompetent mice: establishment of a new transplantable in vivo model for malignant glioma. J Neurosurg 2007; 106: 652-659. (Pubitemid 46536463)
23. Grunda JM, Fiveash J, Palmer CA, Cantor A, Fathallah-Shaykh HM, Nabors LB et al. Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome. Clin Cancer Res 2010; 16: 2890-2898.
24. Cascino TL, Veeder MH, Buckner JC, O'Fallon JR, Wiesenfeld M, Levitt R et al. Phase II study of 5-fluorouracil and leucovorin in recurrent primary brain tumor. J Neurooncol 1996; 30: 243-246. (Pubitemid 26377548)
25. Levin VA, Edwards MS, Wara WM, Allen J, Ortega J, Vestnys P. 5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. Neurosurgery 1984; 14: 679-681. (Pubitemid 14088266)
26. Stewart DJ, Dahrouge S, Soltys K. A phase II study of 5-fluorouracil plus folinic acid in malignant gliomas in adults. J Neurooncol 1995; 23: 249-252.
27. Menei P, Capelle L, Guyotat J, Fuentes S, Assaker R, Bataille B et al. Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. Neurosurgery 2005; 56: 242-248.
28. Menei P, Jadaud E, Faisant N, Boisdron-Celle M, Michalak S, Fournier D et al. Stereotaxic implantation of 5-fluorouracil-releasing microspheres in malignant glioma. Cancer 2004; 100: 405-410. (Pubitemid 38063652)
29. Bourke RS, West CR, Chheda G, Tower DB. Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate. Cancer Res 1973; 33: 1735-1746.
30. 14C and its metabolites in a murine glioma. J Natl Cancer Inst 1972; 49: 1577-1584.
31. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117: 268-275.
32. Zhang N, Yin Y, Xu SJ, Chen WS. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules 2008; 13: 1551-1569.
33. Fine R, Fogelman D, Schreibman S. ASCO Annual Meeting Proceedings. J Clin Onco 2005; 23: 4216.
34. Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006; 107: 1348-1354. (Pubitemid 44452785)
35. Raymond E, Izbicka E, Soda H, Gerson SL, Dugan M, Von Hoff DD. Activity of temozolomide against human tumor colony-forming units. Clin Cancer Res 1997; 3: 1769-1774. (Pubitemid 27444716)